GILD Gilead Sciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

GILD [NASD]

Gilead Sciences, Inc.

Healthcare | Drug Manufacturers - General | USA

statements

Index	S&P 500	P/E	-	EPS (ttm)	-0.24	Insider Own	0.41%	Shs Outstand	1.26B	Perf Week	-6.11%
Market Cap	77.09B	Forward P/E	8.68	EPS next Y	6.98	Insider Trans	-0.64%	Shs Float	1.25B	Perf Month	-5.70%
Income	-257.00M	PEG	-	EPS next Q	1.96	Inst Own	81.50%	Short Float	1.55%	Perf Quarter	-20.59%
Sales	22.17B	P/S	3.48	EPS this Y	1.10%	Inst Trans	0.12%	Short Ratio	2.15	Perf Half Y	-25.53%
Book/sh	14.36	P/B	4.22	EPS next Y	-0.14%	ROA	-0.40%	Target Price	78.42	Perf Year	-7.15%
Cash/sh	14.86	P/C	4.08	EPS next 5Y	0.59%	ROE	-1.20%	52W Range	59.85 - 85.97	Perf YTD	-6.82%
Dividend	2.72	P/FCF	14.90	EPS past 5Y	-10.50%	ROI	9.50%	52W High	-29.93%	Beta	0.52
Dividend %	4.49%	Quick Ratio	2.20	Sales past 5Y	-2.00%	Gross Margin	78.60%	52W Low	0.64%	ATR	1.35
Employees	11800	Current Ratio	2.30	Sales Q/Q	-9.50%	Oper. Margin	-4.30%	RSI (14)	32.88	Volatility	1.96% 1.84%
Optionable	Yes	Debt/Eq	1.34	EPS Q/Q	-280.70%	Profit Margin	-1.20%	Rel Volume	0.84	Prev Close	60.55
Shortable	Yes	LT Debt/Eq	1.17	Earnings	Oct 28 AMC	Payout	-	Avg Volume	9.02M	Price	60.24
Recom	2.50	SMA20	-4.12%	SMA50	-7.05%	SMA200	-15.36%	Volume	3,308,591	Change	-0.51%

Sep-30-20

Resumed

Jefferies

Buy

$78

Sep-15-20

Upgrade

Maxim Group

Hold → Buy

$88

Jul-31-20

Reiterated

Wells Fargo

Equal Weight

$87 → $76

Jul-31-20

Reiterated

SunTrust

Hold

$73 → $74

Jul-31-20

Reiterated

RBC Capital Mkts

Outperform

$89 → $87

Jul-31-20

Reiterated

Piper Sandler

Overweight

$90 → $85

Jul-31-20

Reiterated

Morgan Stanley

Equal-Weight

$80 → $79

Jul-31-20

Reiterated

Credit Suisse

Neutral

$75 → $73

Jul-20-20

Upgrade

Credit Suisse

Underperform → Neutral

$64 → $75

Jun-03-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$85 → $94

May-26-20

Upgrade

SunTrust

Sell → Hold

$73

May-01-20

Downgrade

SunTrust

Hold → Sell

$70

May-01-20

Downgrade

Raymond James

Outperform → Mkt Perform

May-01-20

Downgrade

JP Morgan

Overweight → Neutral

Apr-27-20

Downgrade

UBS

Buy → Neutral

$77 → $80

Apr-20-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$87

Apr-20-20

Downgrade

BMO Capital Markets

Outperform → Market Perform

$79

Apr-17-20

Downgrade

CFRA

Hold → Sell

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Mar-20-20

Upgrade

Piper Sandler

Neutral → Overweight

$70 → $90

Oct-21-20 12:00PM	Fauci Tells Doctors Covid is Worse in the U.S. Because of a Failure to Avoid Crowds Barrons.com
10:37AM	Dozens of volunteers to be deliberately infected with COVID-19 in effort to speed up vaccine development MarketWatch
07:44AM	Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings? Zacks
07:01AM	Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans Business Wire
06:09AM	Better Buy: Moderna vs. Gilead Sciences Motley Fool
Oct-20-20 05:45PM	Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
02:55PM	Were Hedge Funds Right About Souring On Gilead Sciences, Inc. (GILD)? Insider Monkey
02:11PM	Covid-19 Vaccines Could Take a Critical Next Step in November Just Not In Time for the Election Barrons.com
09:02AM	Gilead Coronavirus Drug Treated President But Is GILD Stock A Buy? Investor's Business Daily
08:00AM	Is Gilead Sciences a Good Coronavirus Stock? Motley Fool
05:30AM	Gilead Stands Up for Its Covid and HIV Drugs Barrons.com
02:30AM	UK launches world's first human challenge trial for COVID-19 with Irish company hVivo Yahoo Finance
Oct-19-20 04:32PM	The most difficult phase of the epidemic is ahead of us: doctor Yahoo Finance Video
02:40PM	'Not just him': What Trump's antibody use says about the future of coronavirus treatments Yahoo Finance
01:35PM	Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion Zacks
11:00AM	Can Gilead Make Money From Its COVID-19 Treatment Remdesivir? Motley Fool
08:30AM	Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020 Business Wire
Oct-18-20 06:42AM	Does This Metric Tell Investors All They Need to Know About Gilead Sciences? Motley Fool
Oct-17-20 03:57AM	Gilead Sciences, Inc. -- Moody's affirms Gilead at A3; outlook revised to negative Moody's
Oct-16-20 03:38PM	I think were at the beginning of a third surge of coronavirus: Advancing Health Equity CEO Yahoo Finance Video
03:36PM	Coronavirus Latest: Friday, October 16 Yahoo Finance Video
03:24PM	Misinformation is the 'biggest concern' leading up to election: CrowdStrike President Yahoo Finance Video
01:53PM	Can Cytonics Pivot Successfully to Covid-19 Therapeutics? InvestorPlace
01:25PM	WHO Questions Effectiveness of Remdesivir on Covid-19 Death Rates Barrons.com
11:22AM	Gloomy COVID drug data shows why big, randomised trials matter Reuters
11:04AM	Coronavirus update: Global COVID-19 cases top 38.9 million as trial of promising therapy finds it does not stop patients dying MarketWatch
09:56AM	WHO: Remdesivir Does Not Substantially Affect COVID-19 Patient Mortality Motley Fool
09:33AM	Gilead Sciences Slides After WHO Study Doubts Remdesivir Effectiveness TheStreet.com
08:02AM	Boeing, Pfizer, Gilead, Covid-19 - 5 Things You Must Know Friday TheStreet.com
07:57AM	Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients MarketWatch
07:28AM	European CHMP Adopts Positive Opinion for Kites KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Business Wire
06:52AM	US STOCKS-Futures perk up on vaccine hopes as stimulus stand-off weighs Reuters
06:35AM	Coronavirus tally: Global cases of COVID-19 38.9 million, 1.09 million deaths and U.S. nears 8 million cases MarketWatch
06:24AM	Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint Reuters
06:13AM	WHO defends data after concluding Gilead's remdesivir flopped COVID trial Reuters
06:04AM	Analysis: Sales of first big COVID-19 drug, remdesivir, may disappoint Reuters
04:05AM	Gilead's Remdesivir Ineffective In COVID-19 Patients, WHO Study Finds Benzinga
02:10AM	Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference PR Newswire
Oct-15-20 08:50PM	PRESS DIGEST- Financial Times - Oct. 16 Reuters
05:00PM	Diodes Incorporated to Announce Third Quarter 2020 Financial Results on November 9 Business Wire
04:25PM	Remdesivir didn't reduce mortality among COVID-19 in WHO study: Report MarketWatch
03:56PM	WHO study says remdesivir did not reduce mortality in COVID-19 patients - FT Reuters
09:41AM	Coronavirus second wave looms: 'Hope for the best but prepare for the worst' Yahoo Finance
Oct-14-20 04:44PM	The medical community has learnt a lot and are better prepared for the next phase: doctor Yahoo Finance Video
04:29PM	Coronavirus Latest: Wednesday, October 14 Yahoo Finance Video
04:01PM	Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 Business Wire
10:48AM	Eli Lilly's COVID-19 Treatment Candidate Has a Manufacturing Site Problem Motley Fool
10:10AM	Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates Zacks
08:30AM	Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer Business Wire
07:32AM	NIH confirms trial for Lilly antibody treatment is paused MarketWatch
Oct-13-20 05:45PM	Gilead Sciences (GILD) Stock Moves -0.09%: What You Should Know Zacks
04:24PM	Eli Lilly Pauses Covid-19 Treatment Clinical Trials Over Safety Concerns Investor's Business Daily
03:20PM	A study testing Lilly's antibody treatment and remdesivir is paused MarketWatch
03:10PM	Gilead & Galapagos Announce Positive Data on UC Candidate Zacks
12:48PM	NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr MarketWatch
11:29AM	NIH starts clinical trial testing antibody treatments in COVID-19 patients Reuters
08:09AM	Is Gilead Sciences a Good Coronavirus Stock to Buy? Motley Fool
Oct-12-20 05:23PM	Pfizer Suit Could Be an Earthquake for Drug Pricing Barrons.com
03:12PM	COVID SCIENCE-COVID-19 antibodies last at least 3 months; so do symptoms for many Reuters
10:45AM	Gilead Up on Positive Final Results for Coronavirus Treatment Zacks
09:55AM	Stock Market News for Oct 12, 2020 Zacks
09:52AM	Gilead Sciences's Debt Overview Benzinga
09:15AM	Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis Business Wire
07:20AM	LabCorp Has Been Tested by Covid-19. But Its Now on a Roll. Barrons.com
Oct-11-20 09:32AM	Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories? Motley Fool
07:06AM	If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now Motley Fool
07:04AM	Is Gilead Sciences a Buy? Motley Fool
Oct-10-20 07:00AM	Alaska Bought Up Gilead, Lilly, and Wells Fargo Stock. Heres What It Sold. Barrons.com
Oct-09-20 08:43PM	Forget Economic Stimulus. This Is Why the Dow Had a Great Week. Barrons.com
04:16PM	S&P 500 Has Best Week Since July as White House Plans $1.8 Trillion Stimulus Package Barrons.com
04:15PM	Coronavirus Latest: Friday, October 9 Yahoo Finance Video
12:48PM	White House Preparing New $1.8 Trillion Stimulus Offer Barrons.com
12:35PM	Gilead Sciences agrees to sell to Europe up to 500,000 courses of remdesivir MarketWatch
11:48AM	Pfizer Is a Value Play in the Covid-19 Frenzy InvestorPlace
10:12AM	Gilead's Veklury Study Shows Faster COVID-19 Recovery, Reduced Disease Progression, Mortality Benzinga
10:12AM	Need More Proof That Gileads Treatment Helps Covid Patients? You Just Got It. Barrons.com
10:02AM	Gilead Shares Gain Following Positive Data From Final Remdesivir Trial TheStreet.com
05:45AM	Wall Street Opens Higher as Faith in Stimulus Persists; Dow up 130 Pts Investing.com
Oct-08-20 10:13PM	Gilead's remdesivir shaved five days off COVID-19 recovery time, reduced risk of death in some Reuters
10:10PM	Is Gilead Stock a Buy Right Now? This Is What You Need to Know TipRanks
05:33PM	Late-stage study of COVID-19 convalescent-plasma treatment with remdesivir starts Reuters
05:05PM	Final Results of National Institute of Allergy and Infectious Diseases ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19 Business Wire
04:14PM	Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply Deal Investor's Business Daily
12:22PM	Dow Jones Gives Up Gains As Stocks Weaken On Jobless Claims Data Investor's Business Daily
08:31AM	Regeneron's stock rallies after it announces EUA request for antibody treatment MarketWatch
07:52AM	The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street Benzinga
05:59AM	Gilead Inks EU Supply Deal For 500,000 Remdesivir Doses SmarterAnalyst
04:38AM	EU signs joint procurement contract for remdesivir supply Reuters
03:00AM	Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir) Business Wire
Oct-07-20 04:34PM	Eli Lilly Files Emergency Use Authorization Request For A Covid-19 Therapy Investor's Business Daily
12:57PM	The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia Zacks
11:27AM	Coronavirus update: Eli Lilly eyes emergency use for antibodies; Trump fumes over FDA vaccine guidelines Yahoo Finance
10:24AM	Current Outlook Gloomy Zacks
Oct-06-20 05:45PM	Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
12:39PM	DICK'S, Las Vegas Sands, Regeneron, Gilead and Eli Lilly as Zacks Bull and Bear of the Day Zacks
10:04AM	Remdesivir Shortage Fears Rise as Trump Gets Treatment TheStreet.com
08:15AM	SVB Leerink analysts predict $1 billion in peak sales of Regeneron's experimental COVID-19 treatment MarketWatch
06:08AM	Trump's COVID-19 Treatment: Here Are the Stocks of All the Drugmakers Involved Motley Fool
Oct-05-20 05:47PM	Ligand: The Small Cap Powering Gilead's Remdesivir Benzinga
04:28PM	Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President Investor's Business Daily

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Whitley Richard James	Director	Oct 01	Option Exercise	0.00	1,434	0	31,122	Oct 05 07:09 PM
Parsey Merdad	Chief Medical Officer	Aug 17	Sale	68.32	182	12,434	0	Aug 19 12:53 PM
Mercier Johanna	Chief Commercial Officer	Jul 24	Option Exercise	0.00	7,505	0	7,505	Jul 28 06:47 PM
Rodriguez Javier	Director	Jun 23	Sale	75.50	189	14,270	0	Jun 25 01:51 PM
Dickinson Andrew D	EVP, Chief Financial Officer	Jun 10	Option Exercise	0.00	3,646	0	15,046	Jun 12 03:28 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Option Exercise	39.76	13,210	525,225	27,854	May 07 06:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	May 05	Sale	79.23	13,210	1,046,640	14,644	May 07 06:02 PM
Cogan John Francis	Director	May 04	Option Exercise	19.63	2,416	47,426	57,276	May 05 04:28 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Option Exercise	66.36	11,486	762,211	23,685	May 06 06:40 PM
Wilfong Diane E.	SVP, Controller & CAO	May 04	Sale	80.09	12,264	982,220	11,421	May 06 06:40 PM
Cogan John Francis	Director	May 04	Sale	81.75	2,416	197,508	54,860	May 05 04:28 PM
Cogan John Francis	Director	Apr 27	Option Exercise	19.63	2,413	47,367	57,273	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 27	Sale	79.90	2,413	192,799	54,860	Apr 29 07:28 PM
Cogan John Francis	Director	Apr 20	Option Exercise	19.63	2,413	47,367	57,273	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 20	Sale	83.00	2,413	200,279	54,860	Apr 21 07:42 PM
Cogan John Francis	Director	Apr 13	Option Exercise	19.63	2,413	47,367	57,273	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 13	Sale	75.90	2,413	183,147	54,860	Apr 14 03:52 PM
Cogan John Francis	Director	Apr 06	Option Exercise	19.63	2,413	47,367	57,273	Apr 07 05:34 PM
Cogan John Francis	Director	Apr 06	Sale	79.52	2,413	191,882	54,860	Apr 07 05:34 PM
Cogan John Francis	Director	Mar 30	Option Exercise	19.63	2,413	47,367	57,273	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 30	Sale	75.35	2,413	181,820	54,860	Mar 31 03:00 PM
Cogan John Francis	Director	Mar 23	Option Exercise	19.63	2,413	47,367	57,273	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 23	Sale	75.27	2,413	181,627	54,860	Mar 24 08:42 PM
Cogan John Francis	Director	Mar 16	Option Exercise	19.63	2,413	47,367	57,273	Mar 17 08:01 PM
Cogan John Francis	Director	Mar 16	Sale	67.26	2,413	162,298	54,860	Mar 17 08:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Option Exercise	24.30	2,950	71,670	17,594	Mar 12 08:30 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 10	Sale	75.55	2,950	222,873	14,644	Mar 12 08:30 PM
Cogan John Francis	Director	Mar 09	Option Exercise	19.63	2,413	47,367	57,273	Mar 10 09:16 PM
Cogan John Francis	Director	Mar 09	Sale	77.97	2,413	188,142	54,860	Mar 10 09:16 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Mar 02	Sale	70.88	10,441	740,014	14,644	Mar 03 07:40 PM
Lofton Kevin E	Director	Feb 24	Option Exercise	19.63	21,720	426,364	86,579	Feb 25 05:13 PM
WILSON GAYLE E	Director	Feb 10	Option Exercise	19.63	21,720	426,364	148,502	Feb 11 07:02 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Option Exercise	24.30	2,950	71,670	27,640	Feb 12 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 10	Sale	69.32	2,950	204,494	24,690	Feb 12 06:25 PM
WILSON GAYLE E	Director	Feb 10	Sale	67.72	21,720	1,470,878	126,782	Feb 11 07:02 PM
WOLD OLSEN PER	Director	Feb 07	Option Exercise	20.65	20,282	418,722	118,136	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 07	Sale	70.00	1,426	99,820	24,690	Feb 10 07:00 PM
WOLD OLSEN PER	Director	Feb 07	Sale	69.00	20,282	1,399,458	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Option Exercise	40.56	5,000	202,800	29,690	Feb 10 07:00 PM
WOLD OLSEN PER	Director	Feb 06	Option Exercise	19.63	21,720	426,364	119,574	Feb 10 06:25 PM
WOLD OLSEN PER	Director	Feb 06	Sale	68.12	21,720	1,479,605	97,854	Feb 10 06:25 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Feb 06	Sale	68.18	5,000	340,901	24,690	Feb 10 07:00 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Option Exercise	24.30	2,950	71,670	20,014	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Jan 03	Sale	64.63	2,950	190,659	17,064	Jan 06 07:01 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Option Exercise	24.30	5,900	143,341	22,964	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Dec 03	Sale	65.77	5,900	388,043	17,064	Dec 04 07:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Option Exercise	40.56	15,000	608,400	32,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 25	Sale	66.85	15,000	1,002,809	17,064	Nov 26 02:14 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 19	Sale	64.91	10,000	649,062	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Option Exercise	24.30	10,000	242,950	27,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 18	Sale	63.85	10,000	638,500	17,064	Nov 20 06:11 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 05	Sale	66.06	2,095	138,404	17,826	Nov 07 08:04 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Option Exercise	16.89	2,400	40,536	23,921	Nov 05 08:21 PM
Pletcher Brett A	EVP,Corp Affairs & Gen Counsel	Nov 01	Sale	64.52	4,000	258,099	19,921	Nov 05 08:21 PM
Pletcher Brett A	EVP, Gen Counsel & Corp Sec	Oct 28	Sale	63.31	5,677	359,412	21,521	Oct 30 08:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience